Cabotegravir (Apretude)

CADTH recommends that Apretude should be reimbursed by public drug plans for at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, if certain conditions are met. Apretude should only be covered by public drug plans in a similar manner to tenofovir disoproxil fumarate–emtricitabine (TDF-FTC) for of HIV-1 PrEP. Apretude should only be reimbursed if there is a reduction in price and if the economic feasibility of the adoption of Apretude is addressed.